Impacting our Commercial line of business only.
As outlined in our April 10, 2025, HealthCare News article Coming Soon: Stelara Biosimilar Product Changes, effective July 1, 2025, Selarsdi (ustekinumab-aekn), Steqeyma (ustekinumab-stba), and Yesintek (ustekinumab-kfce) will be the preferred Stelara biosimilar products on all Blue Cross Blue Shield of North Dakota (BCBSND) formularies. Stelara will be removed from formularies and will be a non-preferred medication. Current coverage for Stelara will remain the same through June 30, 2025.
Members who are part of the Exclusive Specialty Pharmacy Network with Accredo and Prime Therapeutics Pharmacy (PTP) will have access to Selarsdi at PTP. Steqeyma and Yesintek can be filled at either Accredo or PTP.
Members who are part of the Limited Preferred Specialty Network should check with the in-network specialty pharmacy of choice prior to sending a biosimilar prescription.
Questions?
Refer to the full article at Coming Soon: Stelara Biosimilar Product Changes. Providers can also contact PTP at 800-424-1708 or BCBSND Provider Service Center at 800-368-2312.
